Targeting viral condensates could be a valuable strategy for developing fast-acting, specifically targeted drugs with a potential broad spectrum of activity against pathogenic viruses, including respiratory syncytial virus (RSV), by targeting proteins critical for condensate formation, according to an international collaborative study.